Licensing status

Publication and contact information

Infectious disease

Herpes simplex virus (HSV); cytomegalovirus (CMV)

Lysine-specific demethylase 4 (KDM4; JMJD2)

Cell culture and explanted mouse ganglia studies suggest JMJD2 inhibitors could be used to treat primary HSV-1 infection and prevent reactivation. In cultured human cell lines, the JMJD2 inhibitor ML324 blocked early expression of HSV-1 genes with an IC50 of about 10 mM and caused dose-dependent decreases in viral replication compared with acyclovir. In mouse ganglia infected with latent HSV-1, the inhibitor decreased viral reactivation compared with acyclovir. Ongoing work includes studying the inhibitor in a mouse model of primary HSV infection.
Acyclovir is a generic used to treat HSV infection.

SciBX 6(4); doi:10.1038/scibx.2013.89
Published online Jan. 31, 2013

Patented; available for licensing from the National Institute of Allergy and Infectious Diseases (NIAID)
Contact: Ken Pekoc, Office of Technology Development, NIAID, Bethesda, Md.

Contact: Tedd Fenn, same affiliation as above

Liang, Y. et al. Sci. Transl. Med.; published online Jan. 9, 2013;
Contact: Thomas M. Kristie, National Institutes of Health, Bethesda, Md.